253 related articles for article (PubMed ID: 29753381)
1. Denosumab-Associated Severe Hypocalcemia in a Patient With Chronic Kidney Disease.
Salim SA; Nair LR; Thomas L; Garla V; Palabindala V; Agarwal M; Fülöp T
Am J Med Sci; 2018 May; 355(5):506-509. PubMed ID: 29753381
[TBL] [Abstract][Full Text] [Related]
2. Hypocalcemia post denosumab in patients with chronic kidney disease stage 4-5.
Dave V; Chiang CY; Booth J; Mount PF
Am J Nephrol; 2015; 41(2):129-37. PubMed ID: 25790847
[TBL] [Abstract][Full Text] [Related]
3. Hypercalcaemia-induced acute kidney injury in an older patient with osteoporosis treated with alfacalcidol for denosumab-induced hypocalcaemia.
Yamada S; Matsuo M; Tokumoto M; Ooboshi H
Nephrology (Carlton); 2017 Jul; 22(7):572-573. PubMed ID: 28621008
[No Abstract] [Full Text] [Related]
4. Life-threatening hypocalcaemia associated with denosumab in advanced chronic kidney disease.
Killen JP; Yong K; Luxton G; Endre Z
Intern Med J; 2016 Jun; 46(6):746-7. PubMed ID: 27257154
[No Abstract] [Full Text] [Related]
5. Rapid progression of vascular and soft tissue calcification while being managed for severe and persistent hypocalcemia induced by denosumab treatment in a patient with multiple myeloma and chronic kidney disease.
Ueki K; Yamada S; Tsuchimoto A; Tokumoto M; Kumano T; Kitazono T; Tsuruya K
Intern Med; 2015; 54(20):2637-42. PubMed ID: 26466702
[TBL] [Abstract][Full Text] [Related]
6. Denosumab in hypercalcemia of malignancy: a case series.
Dietzek A; Connelly K; Cotugno M; Bartel S; McDonnell AM
J Oncol Pharm Pract; 2015 Apr; 21(2):143-7. PubMed ID: 24415364
[TBL] [Abstract][Full Text] [Related]
7. High serum ALP level is associated with increased risk of denosumab-related hypocalcemia in patients with bone metastases from solid tumors.
Kinoshita Y; Arai M; Ito N; Takashi Y; Makita N; Nangaku M; Shinoda Y; Fukumoto S
Endocr J; 2016 May; 63(5):479-84. PubMed ID: 26860123
[TBL] [Abstract][Full Text] [Related]
8. Hypocalcaemic tetany occurring post a single denosumab dose in a patient with stage 4 chronic kidney disease, followed by calcium- and calcitriol-induced hypercalcaemia.
Lambe G; Malvathu R; Thomas HM; Graves A
Nephrology (Carlton); 2015 Aug; 20(8):583-4. PubMed ID: 26194986
[No Abstract] [Full Text] [Related]
9. Severe Hypocalcemia Associated With Denosumab in Metastatic Castration-Resistant Prostate Cancer: Risk Factors and Precautions for Treating Physicians.
Autio KA; Farooki A; Glezerman IG; Chan A; Schneider CW; Barr HC; Seyboth BM; Kampel LJ; Danila DC; Rathkopf DE; Slovin SF; Scher HI; Morris MJ
Clin Genitourin Cancer; 2015 Aug; 13(4):e305-e309. PubMed ID: 25559408
[No Abstract] [Full Text] [Related]
10. Impaired residual renal function predicts denosumab-induced serum calcium decrement as well as increment of bone mineral density in non-severe renal insufficiency.
Miyaoka D; Imanishi Y; Ohara M; Hayashi N; Nagata Y; Yamada S; Mori K; Emoto M; Inaba M
Osteoporos Int; 2019 Jan; 30(1):241-249. PubMed ID: 30187112
[TBL] [Abstract][Full Text] [Related]
11. Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: a meta-analysis of observational studies.
Thongprayoon C; Acharya P; Acharya C; Chenbhanich J; Bathini T; Boonpheng B; Sharma K; Wijarnpreecha K; Ungprasert P; Gonzalez Suarez ML; Cheungpasitporn W
Osteoporos Int; 2018 Aug; 29(8):1737-1745. PubMed ID: 29713798
[TBL] [Abstract][Full Text] [Related]
12. Safety of denosumab in dialysis patients on calcium and vitamin D supplements.
Ullah A; Abdulnabi K; Khalil A; Alexander J; Pai P; Mishra V
Saudi J Kidney Dis Transpl; 2017; 28(1):158-161. PubMed ID: 28098118
[No Abstract] [Full Text] [Related]
13. Severe hypocalcemia after denosumab administration in a patient with chronic kidney disease: a case report.
Kouroglou E; Tsiama V; Dionysopoulou S; Gavriiloglou G; Bora M; Belis K; Proikaki S; Savvidis C; Giannou P; Petras D
J Musculoskelet Neuronal Interact; 2023 Jun; 23(2):285-289. PubMed ID: 37259667
[TBL] [Abstract][Full Text] [Related]
14. Denosumab anf cronic kidney disease: Severe life-threatening hypocalcemia.
Monge Rafael P; Martin de Francisco ÁL; Fernández-Fresnedo G
Nefrologia (Engl Ed); 2018; 38(1):97-98. PubMed ID: 29325673
[No Abstract] [Full Text] [Related]
15. High bone turnover status as a risk factor in symptomatic hypocalcemia following denosumab treatment in a male patient with osteoporosis.
Ishikawa K; Nagai T; Tsuchiya K; Oshita Y; Kuroda T; Ito H; Tani S; Dodo Y; Toyone T; Inagaki K
Clin Interv Aging; 2018; 13():1929-1934. PubMed ID: 30349211
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of denosumab in osteoporotic hemodialysed patients.
Festuccia F; Jafari MT; Moioli A; Fofi C; Barberi S; Amendola S; Sciacchitano S; Punzo G; Menè P
J Nephrol; 2017 Apr; 30(2):271-279. PubMed ID: 27394428
[TBL] [Abstract][Full Text] [Related]
17. A RANKL Wrinkle: Denosumab-Induced Hypocalcemia.
Laskowski LK; Goldfarb DS; Howland MA; Kavcsak K; Lugassy DM; Smith SW
J Med Toxicol; 2016 Sep; 12(3):305-8. PubMed ID: 26987988
[TBL] [Abstract][Full Text] [Related]
18. Denosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting.
Huynh AL; Baker ST; Stewardson AJ; Johnson DF
Pharmacoepidemiol Drug Saf; 2016 Nov; 25(11):1274-1278. PubMed ID: 27255807
[TBL] [Abstract][Full Text] [Related]
19. Effect of denosumab versus zoledronic acid on calcium levels in cancer patients with bone metastasis: A retrospective cohort study.
Nasser SM; Sahal A; Hamad A; Elazzazy S
J Oncol Pharm Pract; 2019 Dec; 25(8):1846-1852. PubMed ID: 31694497
[TBL] [Abstract][Full Text] [Related]
20. In brief: Severe hypocalcemia with denosumab (Prolia) in chronic kidney disease.
Med Lett Drugs Ther; 2024 Mar; 66(1697):40. PubMed ID: 38412278
[No Abstract] [Full Text] [Related]
[Next] [New Search]
